May 20, 2024 9:15am EDT Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
May 14, 2024 4:15pm EDT Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
May 06, 2024 7:00am EDT Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Mar 19, 2024 7:30am EDT Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Mar 11, 2024 7:30am EDT Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Feb 29, 2024 4:05pm EST Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Feb 14, 2024 7:30am EST Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Dec 21, 2023 8:00am EST Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Dec 14, 2023 4:15pm EST Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
